“Hepatitis b”的搜索结果，显示 351-360 项，共有 9257 项

1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell ...

2. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... B cell malignancies by engineering T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T-cells have ...

3. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... B cell malignancies by engineering T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T-cells have ...

4. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   ... B cell malignancies by engineering T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T-cells have ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

6. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell ...

8. 血液科- 临床试验- 妙佑医疗国际

   AZD0486 As Monotherapy In Participants With Relapsed/Refractory (R/R) B-cell NHL ... B-cell non-Hodgkin lymphoma (NHL) who have received at least two prior ...

9. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   The chimeric antigen receptor (CAR) T-cell therapy is a revolutionary cellular immunotherapy strategy that has transformed the treatment of B cell malignancies ...

10. 血液科- 临床试验- 妙佑医疗国际

    Inclusion Criteria are the following: age ≥ 18, blood cancer diagnosis (including B-ALL, multiple myeloma, and lymphoma), receiving a CAR-T product, able ...